Connect Biopharmaceuticals is a China-based global clinical-stage company focused on discovery and development of novel immune modulators for the treatment of autoimmune diseases and inflammation. Our drug discovery technology platform is built on the biology of T cell functions, which identifies molecules that target clinical-validated disease pathways. 

Our leading drug candidate is CBP-307, an orally-active, next-generation S1P1 and S1P5 (a G-protein coupled receptor -GPCR) modulator for the treatment of a range of autoimmune disorders, including inflammatory bowel disease, psoriasis, multiple sclerosis and other autoimmune diseases.  We have completed a Phase 1 randomized, double-blind, placebo-controlled study assessed the tolerability, pharmacokinetics, and pharmacodynamics of CBP-307 in Melbourne Australia, and CBP-307 exhibited excellent safety features and potent T cell modulation activity as well as optimal pharmacokinetics and pharmacodynamics profiles, demonstrating the best-in-class potential. CBP-307 is entering Phase 2 studies of ulcerative colitis and Crohn’s disease in H1, 2018.

Our second drug candidate is CBP-201, an antibody that targets IL-4Rα and blocks a central pathway in allergic inflammation, and will be studied for atopic dermatitis, asthma, and other inflammatory condition. CBP-201 is expected to enter Phase 1 clinical study in the first quarter of 2018.  

Additional programs included CBP-174, CBP-233, and CBP-312. To learn more about our program, please see PIPELINE.

TEL/FAX: 0512-53577866

E-MAIL: qchang@connectpharm.com

ADD: 10th Floor, XiangTang Development Building #3 ChaoYang Dong Road, Taicang,Jiangsu Province, China ,215400

Copyright: Suzhou Connect Biopharmaceuticals, Ltd.

Technical support: Epower